361 related articles for article (PubMed ID: 28964443)
21. The accuracy of baseline viral load for predicting the efficacy of elbasvir/grazoprevir in participants with hepatitis C virus genotype 1a infection: An integrated analysis.
Serfaty L; Jacobson I; Rockstroh J; Altice FL; Hwang P; Barr E; Robertson M; Haber B
J Viral Hepat; 2019 Mar; 26(3):329-336. PubMed ID: 30412325
[TBL] [Abstract][Full Text] [Related]
22. Elbasvir/grazoprevir in black adults with hepatitis C virus infection: a pooled analysis of phase 2/3 clinical trials.
Zamor PJ; Vierling J; Ghalib R; Luketic V; Ravendhran N; Balart L; Robertson M; Hwang P; Hanna GJ; Nguyen BY; Barr E; Talwani R; Pearlman B
Am J Gastroenterol; 2018 Jun; 113(6):863-871. PubMed ID: 29695828
[TBL] [Abstract][Full Text] [Related]
23. The efficacy and safety of elbasvir/grazoprevir treatment in HCV genotype 1 patients in Taiwan.
Tsai TC; Deng ST; Hsu CW
J Med Virol; 2020 Feb; 92(2):219-226. PubMed ID: 31599455
[TBL] [Abstract][Full Text] [Related]
24. Cost-Effectiveness Analysis of Pan-Genotypic Sofosbuvir-Based Regimens for Treatment of Chronic Hepatitis C Genotype 1 Infection in China.
Zhou HJ; Cao J; Shi H; Naidoo N; Semba S; Wang P; Fan YF; Zhu SC
Front Public Health; 2021; 9():779215. PubMed ID: 34957030
[No Abstract] [Full Text] [Related]
25. Cost-effectiveness of combination daclatasvir-sofosbuvir for treatment of genotype 3 chronic hepatitis C infection in the United States.
Saint-Laurent Thibault C; Moorjaney D; Ganz ML; Sill B; Hede S; Yuan Y; Gorsh B
J Med Econ; 2017 Jul; 20(7):692-702. PubMed ID: 28294645
[TBL] [Abstract][Full Text] [Related]
26. Cost-Effectiveness Analysis of New HCV Treatments in Egyptian Cirrhotic and Non-Cirrhotic Patients: A Societal Perspective.
Elsisi GH; Aburawash A; Waked E
Value Health Reg Issues; 2017 Sep; 13():7-15. PubMed ID: 29073993
[TBL] [Abstract][Full Text] [Related]
27. Limited drug-drug interaction of elbasvir/grazoprevir for chronic hepatitis C.
Liu CJ; Tseng KC; Lo CC; Tseng IH; Cheng PN
J Formos Med Assoc; 2020 May; 119(5):933-940. PubMed ID: 31594667
[TBL] [Abstract][Full Text] [Related]
28. Treatment outcomes in hepatitis C virus genotype 1a infected patients with and without baseline NS5A resistance-associated substitutions.
Dietz J; Vermehren J; Matschenz K; Buggisch P; Klinker H; Schulze Zur Wiesch J; Hinrichsen H; Peiffer KH; Graf C; Discher T; Trauth J; Schattenberg JM; Piecha F; Mauss S; Niederau C; Müller T; Neumann-Haefelin C; Berg CP; Zeuzem S; Sarrazin C;
Liver Int; 2020 Jul; ():. PubMed ID: 32640072
[TBL] [Abstract][Full Text] [Related]
29. Cost-Utility of All-Oral Direct-Acting Antiviral Regimens for the Treatment of Genotype 1 Chronic Hepatitis C Virus-Infected Patients in Hong Kong.
Yuen MF; Liu SH; Seto WK; Mak LY; Corman SL; Hsu DC; Lee MYK; Khan TK; Puenpatom A
Dig Dis Sci; 2021 Apr; 66(4):1315-1326. PubMed ID: 32385703
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness of currently recommended direct-acting antiviral treatments in patients infected with genotypes 1 or 4 hepatitis C virus in the US.
Saab S; Parisé H; Virabhak S; Wang A; Marx SE; Sanchez Gonzalez Y; Misurski D; Johnson S
J Med Econ; 2016 Aug; 19(8):795-805. PubMed ID: 27063573
[TBL] [Abstract][Full Text] [Related]
31. Elbasvir/grazoprevir for hepatitis C virus genotype 1b East-Asian patients receiving hemodialysis.
Liu CH; Peng CY; Fang YJ; Kao WY; Yang SS; Lin CK; Lai HC; Su WP; Fang SU; Chang CC; Su TH; Liu CJ; Chen PJ; Chen DS; Kao JH
Sci Rep; 2020 Jun; 10(1):9180. PubMed ID: 32513953
[TBL] [Abstract][Full Text] [Related]
32. Elbasvir/Grazoprevir in People With Hepatitis C Genotype 1 Infection and Child-Pugh Class B Cirrhosis: The C-SALT Study.
Jacobson IM; Poordad F; Firpi-Morell R; Everson GT; Verna EC; Bhanja S; Hwang P; Caro L; Robertson M; Charles ED; Platt H
Clin Transl Gastroenterol; 2019 Apr; 10(4):e00007. PubMed ID: 30939489
[TBL] [Abstract][Full Text] [Related]
33. Real-world effectiveness of elbasvir/grazoprevir In HCV-infected patients in the US veterans affairs healthcare system.
Kramer JR; Puenpatom A; Erickson KF; Cao Y; Smith D; El-Serag HB; Kanwal F
J Viral Hepat; 2018 Nov; 25(11):1270-1279. PubMed ID: 29851265
[TBL] [Abstract][Full Text] [Related]
34. Cost-utility analysis of ledipasvir/sofosbuvir for the treatment of genotype 1 chronic hepatitis C in Japan.
Igarashi A; Tang W; Guerra I; Marié L; Cure S; Lopresti M
Curr Med Res Opin; 2017 Jan; 33(1):11-21. PubMed ID: 27609424
[TBL] [Abstract][Full Text] [Related]
35. Safety and tolerability of elbasvir/grazoprevir in chronic hepatitis C virus therapy: Integrated analysis from clinical trials.
Nangia G; Vierling JM; Kwo P; Brown DD; Klopfer SO; Robertson MN; Haber BA; Reddy KR
J Viral Hepat; 2020 Nov; 27(11):1222-1233. PubMed ID: 32594612
[TBL] [Abstract][Full Text] [Related]
36. An integrated analysis of elbasvir/grazoprevir in Korean patients with hepatitis C virus genotype 1b infection.
Lee YJ; Heo J; Kim DY; Chung WJ; Tak WY; Kim YJ; Paik SW; Sim E; Kulasingam S; Talwani R; Haber B; Hwang P
Clin Mol Hepatol; 2019 Dec; 25(4):400-407. PubMed ID: 31132846
[TBL] [Abstract][Full Text] [Related]
37. Real-world experience with Grazoprevir/Elbasvir in the treatment of previously "difficult to treat" patients infected with hepatitis C virus genotype 1 and 4.
Zarębska-Michaluk D; Jaroszewicz J; Buczyńska I; Simon K; Lorenc B; Tudrujek-Zdunek M; Tomasiewicz K; Sitko M; Garlicki A; Janczewska E; Dybowska D; Halota W; Pawłowska M; Pabjan P; Mazur W; Czauż-Andrzejuk A; Berak H; Horban A; Socha Ł; Klapaczyński J; Piekarska A; Blaszkowska M; Belica-Wdowik T; Dobracka B; Tronina O; Deroń Z; Białkowska-Warzecha J; Laurans Ł; Flisiak R
J Gastroenterol Hepatol; 2020 Jul; 35(7):1238-1246. PubMed ID: 31734959
[TBL] [Abstract][Full Text] [Related]
38. Grazoprevir/elbasvir treatment for the relapse of HCV genotype 1b infection after ledipasvir/sofosbuvir: A case report.
Tadokoro T; Morishita A; Oura K; Fujita K; Mimura S; Sakamoto T; Nomura T; Tani J; Yoneyama H; Masaki T
Exp Ther Med; 2018 Aug; 16(2):1026-1028. PubMed ID: 30116355
[TBL] [Abstract][Full Text] [Related]
39. Cost-effectiveness of pan-genotypic direct-acting antiviral regimens for treatment of chronic Hepatitis C in the United States.
Gordon S; Lee J; Smith N; Dieterich D
Expert Rev Pharmacoecon Outcomes Res; 2020 Jun; 20(3):251-257. PubMed ID: 31204882
[TBL] [Abstract][Full Text] [Related]
40. Effectiveness and safety of elbasvir/grazoprevir therapy in patients with chronic HCV infection: Results from the Spanish HEPA-C real-world cohort.
Hernández-Conde M; Fernández I; Perelló C; Gallego A; Bonacci M; Pascasio JM; Romero-Gómez M; Llerena S; Fernández-Rodríguez C; Castro Urda JL; García Buey L; Carmona I; Morillas RM; García ND; Gea F; Carrión JA; Castellote J; Moreno-Planas JM; Piqueras Alcol B; Molina E; Diago M; Montoliu S; de la Vega J; Menéndez F; Sánchez Ruano JJ; García-Samaniego J; Rosales-Zabal JM; Anton MD; Badia E; Souto-Rodríguez R; Salmeron FJ; Fernández-Bermejo M; Figueruela B; Moreno-Palomares JJ; Calleja JL
J Viral Hepat; 2019 Jan; 26(1):55-64. PubMed ID: 30265418
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
